应用两种不同的表达系统对FceR I α亚基的细胞外区进行克隆和表达,表达产物经纯化后用免疫斑点杂交法检测其与IgE结合的能力,探索IgE与其高亲和力受体FceR I α亚基的细胞外区结合的机制。结果两种体系均成功表达出FceRI α亚基的细胞...应用两种不同的表达系统对FceR I α亚基的细胞外区进行克隆和表达,表达产物经纯化后用免疫斑点杂交法检测其与IgE结合的能力,探索IgE与其高亲和力受体FceR I α亚基的细胞外区结合的机制。结果两种体系均成功表达出FceRI α亚基的细胞外区,pBAD/gⅢA表达的FceR I α亚基的细胞外区能与IgE结合,而PQE30表达的FeaR I α亚基的细胞外区不能与IgE结合。提示FccR I α亚基的细胞外区已足够和IgE结合,无需β、γ亚基的存在,其所具有的一定的空间构型和二硫键的形成在与IgE结合时是必需的,而糖基化位点在与IgE的结合时是非必需的。展开更多
Gastrointestinal stromal tumors (GISTs) are often associated with activating KIT mutations, affecting regulatory domains of the KIT tyrosine kinase. Sporadic mastocytosis in adults is usually also caused by KIT mutati...Gastrointestinal stromal tumors (GISTs) are often associated with activating KIT mutations, affecting regulatory domains of the KIT tyrosine kinase. Sporadic mastocytosis in adults is usually also caused by KIT mutations that, however, activate KIT by affecting the intracellular enzymatic site of the molecule. Most GISTs respond to KIT inhibitors that bind to the enzymatic site; in most cases of mastocytosis, however, the modified enzymatic site is not affected by these drugs. We present a kindred with both familial GISTs and mastocytosis that express a novel germline KIT mutation in exon 8, resulting in deletion of codon 419 and affecting the extracellular domain of KIT. This mutation activates KIT, and the mutant KIT is inhibited by the tyrosine kinase inhibitor imatinib mesylate. Our studies identify a new regulatory region in the KIT molecule and strongly suggest that patients with extracellular KIT mutations respond to tyrosine kinase inhibitors.展开更多
文摘应用两种不同的表达系统对FceR I α亚基的细胞外区进行克隆和表达,表达产物经纯化后用免疫斑点杂交法检测其与IgE结合的能力,探索IgE与其高亲和力受体FceR I α亚基的细胞外区结合的机制。结果两种体系均成功表达出FceRI α亚基的细胞外区,pBAD/gⅢA表达的FceR I α亚基的细胞外区能与IgE结合,而PQE30表达的FeaR I α亚基的细胞外区不能与IgE结合。提示FccR I α亚基的细胞外区已足够和IgE结合,无需β、γ亚基的存在,其所具有的一定的空间构型和二硫键的形成在与IgE结合时是必需的,而糖基化位点在与IgE的结合时是非必需的。
文摘Gastrointestinal stromal tumors (GISTs) are often associated with activating KIT mutations, affecting regulatory domains of the KIT tyrosine kinase. Sporadic mastocytosis in adults is usually also caused by KIT mutations that, however, activate KIT by affecting the intracellular enzymatic site of the molecule. Most GISTs respond to KIT inhibitors that bind to the enzymatic site; in most cases of mastocytosis, however, the modified enzymatic site is not affected by these drugs. We present a kindred with both familial GISTs and mastocytosis that express a novel germline KIT mutation in exon 8, resulting in deletion of codon 419 and affecting the extracellular domain of KIT. This mutation activates KIT, and the mutant KIT is inhibited by the tyrosine kinase inhibitor imatinib mesylate. Our studies identify a new regulatory region in the KIT molecule and strongly suggest that patients with extracellular KIT mutations respond to tyrosine kinase inhibitors.
